Open – 12 May
Close – 15 May
Issue Type -100% Book Building Issue
Issue Size – 38,20,000 Equity Shares of Rs. 10/-
Issue Price – Rs 200/- to Rs 210/- Per Equity Share
Maximum Subscription Amount for Retail Investor: Rs 100,000/-
Listing – BSE, NSE
Lead Manager – Almondz Global Securities Ltd
Registrar – Karvy Computershare Pvt Ltd
Phone – 040 23420818
Email – [email protected]
Website – www.karvy.com
Anu’s Laboratories Limited is an ISO 9001:2000 certified company established in 1996, engaged in manufacture of quality drug intermediates to meet the needs of international customers Anu’s Laboratories is one of the leading manufacturers and suppliers of basic and advanced quality drug intermediates and Active Pharmaceutical Ingredients (API) in India. Anu’s Laboratories offers a wide range of complex organic molecules and to extend support to synthesis of new chemical entities. Anu’s Laboratories is an ISO 9001 and Q9001-2000 certified company, strictly conforming to cGMP standards. Company is promoted by Mr. K. Hari Babu.
The optimized process of 2,4-Dichloro-5 Fluoro Acetophenone has enabled the brand to establish itself as the flagship product of the organization. It is available to its wide customer base as a competitive product of the highest quality. Other high quality intermediates such as Chlorohexanone, 1,3-Dibromo Propane is also available to its valued customers. Company is also producing Methyl-4 (4-Chloro 1 oxo butyl) a, a Di-Methyl Acetate. Anu’s Laboratories boasts of a highly qualified team of scientists. Its R&D facilities, located at Balanagar, Hyderabad, support the process of product development, contract research and customised synthesis programmes of the organization. Some big clients are Teva, Israel, Tanabe U.S.A, Dr.Reddy’s Laboratories Ltd, Sun Pharmaceuticals Ltd, Aurobindo Pharma Limited, Divi’s Laboratories Ltd, Nicholas Piramal India Limited and Suven Life Sciences Ltd.
Objects of the issue :
Achieve the benefits of listing on the Stock Exchanges.
Setting up a new plant for manufacturing of drug intermediates including Active Pharmaceutical Ingredients (APIs).
Setting up of pilot plant for carrying out Contract Research and Manufacturing (CRAM).
Meeting long term working capital requirement.
Meeting general corporate purposes.
Meet the expenses of this Issue.